Lineage Cell Therapeutics Stock Forecast
NYSE: LCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 0.94 -1.19%
LCTX analyst consensus
Consensus (7 analysts)
strong_buy
Avg. price target
$5.50+480.41%
- Strong buy 1
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Lineage Cell Therapeutics (2026-10-08), 6 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $5.50, with a high estimate of $9.00 and a low estimate of $3.00. The average target implies upside of 480.4% from the current price of $0.9476.
The spread between the highest and lowest targets is 200.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for LCTX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 14% |
| Buy | 5 | 71% |
| Hold | 1 | 14% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $3.00 | +216.59% |
| Average target | $5.50 | +480.41% |
| High target | $9.00 | +849.77% |